Expression of cortactin in human gliomas and its effect on migration and invasion of glioma cells

Wang,Leilei; Zhao,Kai; Ren,Bingcheng; Zhu,Meng; Zhang,Chen; Zhao,Pengfei; Zhou,Hua; Chen,Lei; Yu,Shenping; Yang,Xuejun

doi:10.3892/or.2015.4156

Expression of cortactin in human gliomas and its effect on migration and invasion of glioma cells

Authors:
- Leilei Wang
- Kai Zhao
- Bingcheng Ren
- Meng Zhu
- Chen Zhang
- Pengfei Zhao
- Hua Zhou
- Lei Chen
- Shenping Yu
- Xuejun Yang
View Affiliations

Affiliations: Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China
Published online on: July 28, 2015 https://doi.org/10.3892/or.2015.4156
Pages: 1815-1824

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the role of cortactin in the infiltrative behavior of glioma cells and the potential mechanism of cortactin in promoting the migration and invasion of glioma cells. The expression of cortactin was detected by immunohistochemistry in 40 human glioma specimens and 8 non-tumor brain specimens. U251, LN229 and SNB19 glioma cells were employed for the in vitro study and assigned into the siRNA-cortactin (transfected with siRNA specific to cortactin), siRNA-NC (transfected with negative control RNA sequence) and siRNA-N (transfected with empty vector) groups. The expression of cortactin in different treated glioma cell groups was detected using western blot analysis and RT-qPCR. The migration and invasion of glioma cells under different treatments were assessed using a wound-healing assay and Transwell-chamber invasion assay, respectively. The lamellipodia of glioma cells following treatment were observed by immunofluorescence (IF) and changes of lamellipodia over time were imaged using an inverted microscope. The distribution of cortactin and the actin-related protein 2/3 (Arp2/3) complex in glioma cells were observed after IF detection. The expression of cortactin in the glioma specimens was significantly higher than that in non-tumor brain tissue (P<0.05) and positively correlated with the malignancy of glioma specimens (r=0.912, P=0.00). The cortactin expression in glioma cells was markedly inhibited (P<0.05) and their migration and invasion ability was also impaired significantly following treatment with siRNA (P<0.05) compared with the other two groups. The size and persistence time of lamellipodia were reduced after cortactin expression was inhibited in glioma cells. Cortactin and the Arp2/3 complex were co-localized in the front of glioma cells, where actin was polymerized and lamellipodia formed. Thus, the results revealed that, cortactin is crucial in invasion and migration of glioma cells, which may promote the migration and invasion of glioma cells by regulating lamellipodia formation, a process requiring the combination of cortactin and the Arp2/3 complex.

View Figures

View References

1	Alqudah MA, Agarwal S, Al-Keilani MS, Sibenaller ZA, Ryken TC and Assem M: NOTCH3 is a prognostic factor that promotes glioma cell proliferation, migration and invasion via activation of CCND1 and EGFR. PLoS One. 8:e772992013. View Article : Google Scholar : PubMed/NCBI
2	Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB and Berens ME: Molecular targets of glioma invasion. Cell Mol Life Sci. 64:458–478. 2007. View Article : Google Scholar : PubMed/NCBI
3	Sciumè G, Santoni A and Bernardini G: Chemokines and glioma: Invasion and more. J Neuroimmunol. 224:8–12. 2010. View Article : Google Scholar : PubMed/NCBI
4	Agudelo-Garcia PA, De Jesus JK, Williams SP, Nowicki MO, Chiocca EA, Liyanarachchi S, Li PK, Lannutti JJ, Johnson JK, Lawler SE, et al: Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. Neoplasia. 13:831–840. 2011. View Article : Google Scholar : PubMed/NCBI
5	Godlewski J, Bronisz A, Nowicki MO, Chiocca EA and Lawler S: microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle. 9:2742–2748. 2010. View Article : Google Scholar : PubMed/NCBI
6	Small JV, Stradal T, Vignal E and Rottner K: The lamellipodium: Where motility begins. Trends Cell Biol. 12:112–120. 2002. View Article : Google Scholar : PubMed/NCBI
7	Yamaguchi H and Condeelis J: Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta. 1773:642–652. 2007. View Article : Google Scholar
8	Wu C, Asokan SB, Berginski ME, Haynes EM, Sharpless NE, Griffith JD, Gomez SM and Bear JE: Arp2/3 is critical for lamellipodia and response to extracellular matrix cues but is dispensable for chemotaxis. Cell. 148:973–987. 2012. View Article : Google Scholar : PubMed/NCBI
9	Suraneni P, Rubinstein B, Unruh JR, Durnin M, Hanein D and Li R: The Arp2/3 complex is required for lamellipodia extension and directional fibroblast cell migration. J Cell Biol. 197:239–251. 2012. View Article : Google Scholar : PubMed/NCBI
10	Goley ED and Welch MD: The ARP2/3 complex: An actin nucleator comes of age. Nat Rev Mol Cell Biol. 7:713–726. 2006. View Article : Google Scholar : PubMed/NCBI
11	Koestler SA, Steffen A, Nemethova M, Winterhoff M, Luo N, Holleboom JM, Krupp J, Jacob S, Vinzenz M, Schur F, et al: Arp2/3 complex is essential for actin network treadmilling as well as for targeting of capping protein and cofilin. Mol Biol Cell. 24:2861–2875. 2013. View Article : Google Scholar : PubMed/NCBI
12	Iwaya K, Norio K and Mukai K: Coexpression of Arp2 and WAVE2 predicts poor outcome in invasive breast carcinoma. Mod Pathol. 20:339–343. 2007. View Article : Google Scholar : PubMed/NCBI
13	Liu Z, Yang X, Chen C, Liu B, Ren B, Wang L, Zhao K, Yu S and Ming H: Expression of the Arp2/3 complex in human gliomas and its role in the migration and invasion of glioma cells. Oncol Rep. 30:2127–2136. 2013.PubMed/NCBI
14	Croucher DR, Rickwood D, Tactacan CM, Musgrove EA and Daly RJ: Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells. Mol Cell Biol. 30:5057–5070. 2010. View Article : Google Scholar : PubMed/NCBI
15	Macgrath SM and Koleske AJ: Cortactin in cell migration and cancer at a glance. J Cell Sci. 125:1621–1626. 2012. View Article : Google Scholar : PubMed/NCBI
16	Weaver AM, Karginov AV, Kinley AW, Weed SA, Li Y, Parsons JT and Cooper JA: Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol. 11:370–374. 2001. View Article : Google Scholar : PubMed/NCBI
17	Weed SA, Karginov AV, Schafer DA, Weaver AM, Kinley AW, Cooper JA and Parsons JT: Cortactin localization to sites of actin assembly in lamellipodiarequires interactions with F-actin and the Arp2/3 complex. J Cell Biol. 29–40. 2000. View Article : Google Scholar
18	Bryce NS, Clark ES, Leysath JL, Currie JD, Webb DJ and Weaver AM: Cortactin promotes cell motility by enhancing lamellipodial persistence. Curr Biol. 15:1276–1285. 2005. View Article : Google Scholar : PubMed/NCBI
19	Dedes KJ, Lopez-Garcia MA, Geyer FC, Lambros MB, Savage K, Vatcheva R, Wilkerson P, Wetterskog D, Lacroix-Triki M, Natrajan R, et al: Cortactin gene amplification and expression in breast cancer: A chromogenic in situ hybridisation and immunohistochemical study. Breast Cancer Res Treat. 124:653–666. 2010. View Article : Google Scholar : PubMed/NCBI
20	Desmarais V, Yamaguchi H, Oser M, Soon L, Mouneimne G, Sarmiento C, Eddy R and Condeelis J: N-WASP and cortactin are involved in invadopodium-dependent chemotaxis to EGF in breast tumor cells. Cell Motil Cytoskeleton. 66:303–316. 2009. View Article : Google Scholar : PubMed/NCBI
21	Hofman P, Butori C, Havet K, Hofman V, Selva E, Guevara N, Santini J and Van Obberghen-Schilling E: Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: Comparison with epidermal growth factor receptor status. Br J Cancer. 98:956–964. 2008. View Article : Google Scholar : PubMed/NCBI
22	Yamada S, Yanamoto S, Kawasaki G, Mizuno A and Nemoto TK: Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma. Pathol Oncol Res. 16:523–531. 2010. View Article : Google Scholar : PubMed/NCBI
23	Perrin BJ, Amann KJ and Huttenlocher A: Proteolysis of cortactin by calpain regulates membrane protrusion during cell migration. Mol Biol Cell. 17:239–250. 2006. View Article : Google Scholar :
24	Giese A, Bjerkvig R, Berens Me and Westphal M: Cost of migration: Invasion of malignant gliomas and implications for treatment. J Clin oncol. 21:1624–1636. 2003. View Article : Google Scholar : PubMed/NCBI
25	Westermark B: Glioblastoma - a moving target. Ups J Med Sci. 117:251–256. 2012. View Article : Google Scholar : PubMed/NCBI
26	Weaver AM: Cortactin in tumor invasiveness. Cancer Lett. 265:157–166. 2008. View Article : Google Scholar : PubMed/NCBI
27	Tehrani S, Faccio R, Chandrasekar I, Ross FP and Cooper JA: Cortactin has an essential and specific role in osteoclast actin assembly. Mol Biol Cell. 17:2882–2895. 2006. View Article : Google Scholar : PubMed/NCBI
28	Hou H, Chen W, Zhao L, Zuo Q, Zhang G, Zhang X, Wang H, Gong H, Li X, Wang M, et al: Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ. J Clin Pathol. 65:1088–1096. 2012. View Article : Google Scholar : PubMed/NCBI
29	Jovčevska I, Kočevar N and Komel R: Glioma and glioblastoma - how much do we (not) know? Mol Clin oncol. 1:935–941. 2013.
30	Rao JS: Molecular mechanisms of glioma invasiveness: The role of proteases. Nat Rev Cancer. 3:489–501. 2003. View Article : Google Scholar : PubMed/NCBI
31	Pfaendtner J, Volkmann N, Hanein D, Dalhaimer P, Pollard TD and Voth GA: Key structural features of the actin filament Arp2/3 complex branch junction revealed by molecular simulation. J Mol Biol. 416:148–161. 2012. View Article : Google Scholar :
32	Chang L, Su J, Jia X and Ren H: Treating malignant glioma in Chinese patients: Update on temozolomide. Onco Targets Ther. 7:235–244. 2014.PubMed/NCBI
33	Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, et al: Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 26:5610–5617. 2008. View Article : Google Scholar : PubMed/NCBI
34	Eisele G, Wick A, Eisele A-C, Clément PM, Tonn J, Tabatabai G, Ochsenbein A, Schlegel U, Neyns B, Krex D, et al: Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neurooncol. 117:141–145. 2014. View Article : Google Scholar : PubMed/NCBI
35	Cheng NC, van Zandwijk N and Reid G: Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5. PLoS One. 9:e903742014. View Article : Google Scholar
36	Yu X, Zech T, McDonald L, Gonzalez EG, Li A, Macpherson I, Schwarz JP, Spence H, Futó K, Timpson P, et al: N-WASP coordinates the delivery and F-actin-mediated capture of MT1-MMP at invasive pseudopods. J Cell Biol. 199:527–544. 2012. View Article : Google Scholar : PubMed/NCBI